April 15, 2019 04:00 AM Eastern Daylight Time - SAN DIEGO--(BUSINESS WIRE)--Librede, a synthetic biology company based in Southern California, has been granted a new patent to produce tetrahydrocannabinolic acid (THCA) in yeast. THCA is the precursor to tetrahydrocannabinol (THC), which is the most well-known cannabinoid; THC has been an FDA approved pharmaceutical compound for decades (a.k.a. dronabinol). The cannabis plant does not produce THC; instead it produces THCA, which is converted to THC by various methods such as heating. The patent issued to Librede shows a process for producing THCA via fermentation using baker’s yeast and low-cost feedstocks. This patent is one of many that Librede has been awarded surrounding the full biosynthesis of cannabinoids, such as cannabidiol (CBD), cannabigerol (CBG), and now THC. Librede plans to continue to expand on its IP portfolio and increase production.
April 15, 2019 04:00 AM Eastern Daylight Time - SAN DIEGO--(BUSINESS WIRE)--Librede, a synthetic biology company based in Southern California, has been granted a new patent to produce tetrahydrocannabinolic acid (THCA) in yeast. THCA is the precursor to tetrahydrocannabinol (THC), which is the most well-known cannabinoid; THC has been an FDA approved pharmaceutical compound for decades (a.k.a. dronabinol). The cannabis plant does not produce THC; instead it produces THCA, which is converted to THC by various methods such as heating. The patent issued to Librede shows a process for producing THCA via fermentation using baker’s yeast and low-cost feedstocks. This patent is one of many that Librede has been awarded surrounding the full biosynthesis of cannabinoids, such as cannabidiol (CBD), cannabigerol (CBG), and now THC. Librede plans to continue to expand on its IP portfolio and increase production.